Shirish Gadgeel MD @umrogelcancer Of University Of Michigan Discusses Update Of KEYNOTE-189 Trial: Evaluated The Addition Of Pembrolizumab To Platinum & Pemetrexed Chemotherapy In Patients With Metastatic Nonsquamous NSCLC.BACKROUND: Pembro + chemo significantly improved OS and PFS over chemo alone and had manageable safety as 1L therapy for metastatic nonsquamous NSCLC in the KEYNOTE-189 study (NCT02578680). The benefit was observed irrespective of PD-L1 TPS. We present updated OS based on longer follow-up and, for the first time, PFS2. METHODS: Eligible pts were randomized 2:1 to pembro (n = 410) or placebo (n = 206) + pemetrexed and carboplatin or cisplatin…
Author: Editor
Shirish Gadgeel MD @umrogelcancer Of University Of Michigan Discusses KEYNOTE-189 Roadmap: Long Term Data & Specific Biomarkers Will Continue To Be Evaluated. BACKROUND: Pembro + chemo significantly improved OS and PFS over chemo alone and had manageable safety as 1L therapy for metastatic nonsquamous NSCLC in the KEYNOTE-189 study (NCT02578680). The benefit was observed irrespective of PD-L1 TPS. We present updated OS based on longer follow-up and, for the first time, PFS2. METHODS: Eligible pts were randomized 2:1 to pembro (n = 410) or placebo (n = 206) + pemetrexed and carboplatin or cisplatin for 4 cycles followed by pembro…
Shirish Gadgeel MD @umrogelcancer Of University Of Michigan Discusses KEYNOTE-189 Questions: Seen Benefit In PD-L1 0 Tumors, Further Follow Up That Compares Pembrolizumab + Chemo To Pembrolizumab Alone. BACKROUND: Pembro + chemo significantly improved OS and PFS over chemo alone and had manageable safety as 1L therapy for metastatic nonsquamous NSCLC in the KEYNOTE-189 study (NCT02578680). The benefit was observed irrespective of PD-L1 TPS. We present updated OS based on longer follow-up and, for the first time, PFS2. METHODS: Eligible pts were randomized 2:1 to pembro (n = 410) or placebo (n = 206) + pemetrexed and carboplatin or cisplatin…
… Qing Xu MD Of Shanghai Tenth Hospital Discusses Watson For Oncology (WFO): Developed With AI To Assist Oncologists In Treatment Decision-Making By Providing Evidence-Based Treatment Recommendations. BACKROUND:IBM Watson for Oncology (WFO) is developed with artificial intelligence to assist the oncologists in treatment decision-making by providing evidence-based treatment recommendations with priority and personality. We have been exploring the value of applying WFO in teaching and remote consulting among members in the hospital union to improve medical quality and conformity. METHODS:Four modes were followed to apply WFO to teaching and remote consulting. Firstly, a teaching hospital conducted instructional teaching for a…
Qing Xu MD Of Shanghai Tenth Hospital Discusses Watson For Oncology (WFO): Developed With AI To Assist Oncologists In Treatment Decision-Making By Providing Evidence-Based Treatment Recommendations. BACKROUND: IBM Watson for Oncology (WFO) is developed with artificial intelligence to assist the oncologists in treatment decision-making by providing evidence-based treatment recommendations with priority and personality. We have been exploring the value of applying WFO in teaching and remote consulting among members in the hospital union to improve medical quality and conformity. METHODS: Four modes were followed to apply WFO to teaching and remote consulting. Firstly, a teaching hospital conducted instructional teaching for…
Toni Choureiri, MD, discusses the biomarker analyses from JAVELIN Renal 101. Background: The phase 3 JAVELIN Renal 101 trial in previously untreated patients (pts) with aRCC demonstrated a progression-free survival (PFS) benefit and higher objective response rate with A+Ax vs S (Motzer, ESMO 2018; LBA6_PR). Here, we report outcomes from biomarker analyses of baseline tumor samples. Methods: We correlated efficacy with the results of molecular analyses of tissue samples from all 886 pts enrolled in JAVELIN Renal 101. Nephrectomy or tumor samples were characterized by immunohistochemistry (CD8 and PD-L1), whole-exome sequencing (WES), and RNAseq. WES and RNAseq were used to…
Tina Cascone MD Of The University of Texas MD Anderson Cancer Center Discusses Toxicity Of Nivolumab & Ipilimumab: Were Still Learning How To Leverage These Treatments In The Pre-Operative Setting. BACKROUND: Neoadjuvant immune checkpoint inhibitors (ICIs) induce major pathologic response (MPR) rates of 20 to 45% in resected NSCLCs. We report the results of NEOSTAR – a phase 2 trial of neoadjuvant N or NI for NSCLCs. METHODS: Pts with stage I-IIIA (single N2) resectable NSCLC (AJCC 7th), PS 0-1, were randomized to N (3 mg/kg IV, D1, 15, 29) or N plus I (1 mg/kg IV, D1) followed by…
Tina Cascone MD Of The University of Texas MD Anderson Cancer Center Discusses Results Of NEOSTAR Study: Study Looked At Neoadjuvant Nivolumab Or Nivolumab Plus Ipilimumab For Resectable NSCLC. BACKROUND: Neoadjuvant immune checkpoint inhibitors (ICIs) induce major pathologic response (MPR) rates of 20 to 45% in resected NSCLCs. We report the results of NEOSTAR – a phase 2 trial of neoadjuvant N or NI for NSCLCs. METHODS: Pts with stage I-IIIA (single N2) resectable NSCLC (AJCC 7th), PS 0-1, were randomized to N (3 mg/kg IV, D1, 15, 29) or N plus I (1 mg/kg IV, D1) followed by surgery…
Dr. Kristin Higgins, MD, discusses the survival benefit of Durvalumab. Background: In the phase 3 PACIFIC study of patients with unresectable, Stage III NSCLC without progression after chemoradiotherapy (CRT), durvalumab demonstrated significant improvements versus placebo in the primary endpoints of progression-free survival (HR, 0.52; 95% CI, 0.4265; P < 0.0001) and overall survival (OS; HR, 0.68; 95% CI, 0.530.87; P = 0.00251). Safety was similar and durvalumab had no detrimental effect on patient-reported outcomes. Here, we report 3-year OS rates for all patients randomized in the PACIFIC study. Methods: Patients with WHO PS 0/1 (any tumor PD-L1 status) who received…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses Why Is CBX-11 Data Significant: Our Platform Technology Is Specific & Only Delivers The Molecule To The Tumor, Can Go In Combo With High Dose Chemotherapeutic Agents. BACKROUND: Poly(ADP-ribose)polymerase inhibitors (PARPis) are a promising new class of anti-cancer agents, but their clinical application has largely been limited to tumors with homologous recombination deficiency (HRD), such as those with BRCA1/2 mutations. One strategy to target HRD-negative tumors with PARPis is to combine them with chemotherapy, although clinical trials indicate that dose-limiting toxicities are a major barrier to achieving synergistic efficacy with these combinations. METHODS:…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses When Will CBX-11 Enter The Clinic: Clinical Program Starting In January Or February Of 2020. BACKROUND: Poly(ADP-ribose)polymerase inhibitors (PARPis) are a promising new class of anti-cancer agents, but their clinical application has largely been limited to tumors with homologous recombination deficiency (HRD), such as those with BRCA1/2 mutations. One strategy to target HRD-negative tumors with PARPis is to combine them with chemotherapy, although clinical trials indicate that dose-limiting toxicities are a major barrier to achieving synergistic efficacy with these combinations. METHODS: We sought to test the hypothesis that HRD-negative cancers can be effectively…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses What Is Alphalex & How Does It Work: Makes Use Of Acidic Tumor Environment To Deliver Anti Cancer Agents Directly Into The Tumor. BACKROUND: Poly(ADP-ribose)polymerase inhibitors (PARPis) are a promising new class of anti-cancer agents, but their clinical application has largely been limited to tumors with homologous recombination deficiency (HRD), such as those with BRCA1/2 mutations. One strategy to target HRD-negative tumors with PARPis is to combine them with chemotherapy, although clinical trials indicate that dose-limiting toxicities are a major barrier to achieving synergistic efficacy with these combinations. METHODS: We sought to test…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses Strategy Of Alphalex Developement: The Agnostic Nature Of The Platform Allows Us To Bring Therapeutics To A Wider Patient Population. BACKROUND: Poly(ADP-ribose)polymerase inhibitors (PARPis) are a promising new class of anti-cancer agents, but their clinical application has largely been limited to tumors with homologous recombination deficiency (HRD), such as those with BRCA1/2 mutations. One strategy to target HRD-negative tumors with PARPis is to combine them with chemotherapy, although clinical trials indicate that dose-limiting toxicities are a major barrier to achieving synergistic efficacy with these combinations. METHODS: We sought to test the hypothesis that…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses How Is Alphalex Different: Its An Antigen Agnostic Tumor Targeting Technology, Can Target Almost Any Solid Tumor In Theory. BACKROUND: Poly(ADP-ribose)polymerase inhibitors (PARPis) are a promising new class of anti-cancer agents, but their clinical application has largely been limited to tumors with homologous recombination deficiency (HRD), such as those with BRCA1/2 mutations. One strategy to target HRD-negative tumors with PARPis is to combine them with chemotherapy, although clinical trials indicate that dose-limiting toxicities are a major barrier to achieving synergistic efficacy with these combinations. METHODS: We sought to test the hypothesis that HRD-negative…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses Cybrexa Additional Candidates: CBX-11 Is The First Of Many Candidates, More Data Will Be Released In The Coming Months. BACKROUND: Poly(ADP-ribose)polymerase inhibitors (PARPis) are a promising new class of anti-cancer agents, but their clinical application has largely been limited to tumors with homologous recombination deficiency (HRD), such as those with BRCA1/2 mutations. One strategy to target HRD-negative tumors with PARPis is to combine them with chemotherapy, although clinical trials indicate that dose-limiting toxicities are a major barrier to achieving synergistic efficacy with these combinations. METHODS: We sought to test the hypothesis that HRD-negative…
Dr. Sanjay Popat, PhD, dicusses Health-related quality of life results from ALTA-1. Background: Results from ALTA-1L (NCT02737501), an international, multicenter trial, showed that brigatinib vs crizotinib as 1L ALK therapy significantly prolongs progression-free survival (PFS; HR: 0.49, 95% CI, 0.33, 0.74) in advanced ALK+ NSCLC. HRQoL was evaluated as a secondary objective. Methods: ALK+ NSCLC patients were randomized 1:1 to brigatinib 90 mg daily for 7 days, then 180 mg daily or crizotinib 250 mg twice daily as 1L ALK therapy; treatment cycles were 28 days. HRQoL was assessed with the EORTC QLQ-C30 and LC13. Change from baseline, duration of…
Dr. Kristin Higgins, MD, discusses how radiation was given in the PACIFIC trials. Background: In the phase 3 PACIFIC study of patients with unresectable, Stage III NSCLC without progression after chemoradiotherapy (CRT), durvalumab demonstrated significant improvements versus placebo in the primary endpoints of progression-free survival (HR, 0.52; 95% CI, 0.4265; P < 0.0001) and overall survival (OS; HR, 0.68; 95% CI, 0.530.87; P = 0.00251). Safety was similar and durvalumab had no detrimental effect on patient-reported outcomes. Here, we report 3-year OS rates for all patients randomized in the PACIFIC study. Methods: Patients with WHO PS 0/1 (any tumor PD-L1…
Dr. Kristin Higgins, MD, disucsses the three-year overall survival update from the PACIFIC trial.Background: In the phase 3 PACIFIC study of patients with unresectable, Stage III NSCLC without progression after chemoradiotherapy (CRT), durvalumab demonstrated significant improvements versus placebo in the primary endpoints of progression-free survival (HR, 0.52; 95% CI, 0.4265; P < 0.0001) and overall survival (OS; HR, 0.68; 95% CI, 0.530.87; P = 0.00251). Safety was similar and durvalumab had no detrimental effect on patient-reported outcomes. Here, we report 3-year OS rates for all patients randomized in the PACIFIC study. Methods: Patients with WHO PS 0/1 (any tumor PD-L1…
Michael R. Migden, M.D., discusses locally advanced cutaneous squamous cell carcinoms. Background: Cemiplimab (REGN2810) produced substantial antitumor activity with durable responses in Phase 1 CSCC expansion cohorts and Phase 2 metastatic (m) CSCC cohort. We now present the primary analysis of the Phase 2 laCSCC cohort (NCT02760498; data cutoff date: Oct 10, 2018). Methods: Pts with laCSCC received cemiplimab 3 mg/kg IV every 2 weeks (Q2W). Tumor measurements were performed Q8W. The primary objective was to evaluate objective response rate (ORR; complete response [CR] + partial response [PR]) according to independent central review (per RECIST 1.1 for scans; modified WHO…
Michael R. Migden, M.D., discusses the phase 2 results of Cemiplimab. Background: Cemiplimab (REGN2810) produced substantial antitumor activity with durable responses in Phase 1 CSCC expansion cohorts and Phase 2 metastatic (m) CSCC cohort. We now present the primary analysis of the Phase 2 laCSCC cohort (NCT02760498; data cutoff date: Oct 10, 2018). Methods: Pts with laCSCC received cemiplimab 3 mg/kg IV every 2 weeks (Q2W). Tumor measurements were performed Q8W. The primary objective was to evaluate objective response rate (ORR; complete response [CR] + partial response [PR]) according to independent central review (per RECIST 1.1 for scans; modified WHO…
Joel Neal MD Of Stanford University Medical Center Discusses Will Our Practice Change: As Of Now TAK-788 Is Not FDA Approved.
Joel Neal MD Of Stanford University Medical Center Discusses What Is EGFR Exon 20 Insertion Mutant NSCLC: 15% Of Lung Cancer In The United States, 50% Overall In Asian Countries.
Joel Neal MD Of Stanford University Medical Center Discusses Results Of TAK-788 Trial: Among 28 Patients That Were Enrolled 43% Had A Response, PFS Was 7.3 Months, Drug Was Well Tolerated Overall.
Joel Neal MD Of Stanford University Medical Center Discusses Efficacy & Tolerance Of TAK-788: Patients Had Diarrhea, Nausea, Mild Rash, & Chemical Pancreatitis, Appears To Be More Potent & Specific In Pre-Clinical Studies.
Karen Reckamp MD @KarenReckampMD Of City of Hope Discusses Who Should We Test: Theres No Screening Study That Has Been Shown To Help Improve Finding The Cancer Early In Non Smokers. BACKROUND: Eligibility for lung cancer screening is based largely on pack-years of smoking, missing many cases. To propose additional groups for screening, this observational study evaluated whether germline mutations associated with cancer risk accelerate onset of lung adenocarcinoma (LA) in ever- and never-smokers. METHODS: Patients with LA and family history of cancer were recruited from our oncology clinic and the Clinical Cancer Genomics Community Research Network. With consent, blood…
Karen Reckamp MD @KarenReckampMD Of City of Hope Discusses Lung Cancer On The Rise: Understanding Why People Are Getting Diagnosed At Earlier Ages Is Important For Prevention & Cure. BACKROUND: Eligibility for lung cancer screening is based largely on pack-years of smoking, missing many cases. To propose additional groups for screening, this observational study evaluated whether germline mutations associated with cancer risk accelerate onset of lung adenocarcinoma (LA) in ever- and never-smokers. METHODS: Patients with LA and family history of cancer were recruited from our oncology clinic and the Clinical Cancer Genomics Community Research Network. With consent, blood samples were…
Karen Reckamp MD @KarenReckampMD Of City of Hope Discusses Germline Mutations In Patients With Lung Cancer: Study Had 104 Patients Who Were Non Smokers & 65 Who Smoked, Looked At 4 Categories Of Germline Gene Mutation. BACKROUND: Eligibility for lung cancer screening is based largely on pack-years of smoking, missing many cases. To propose additional groups for screening, this observational study evaluated whether germline mutations associated with cancer risk accelerate onset of lung adenocarcinoma (LA) in ever- and never-smokers. METHODS: Patients with LA and family history of cancer were recruited from our oncology clinic and the Clinical Cancer Genomics Community…
Dr. Paul Paik, MD, discusses the future of Tepotinib. Background: MET exon 14 skipping (METex14) mutations – reported in 3~4% of NSCLC patients (pts) – are activating, sensitive to MET inhibition and can be conveniently detected using liquid biopsy (LBx). We report data from an ongoing single-arm phase II study of tepotinib, a highly selective MET inhibitor, in NSCLC pts with METex14 mutations identified by LBx or tumor biopsy (TBx) (NCT02864992). Methods: Pts with advanced WT EGFR/ALK NSCLC, prospectively enrolled via either LBx (?60 pts) or TBx (?60 pts, overlap anticipated) central RNA-based METex14 mutation testing, receive tepotinib 500 mg…
Dr. Paul K. Paik, MD, on the Phase II study of Tepotinib. Background: MET exon 14 skipping (METex14) mutations – reported in 3~4% of NSCLC patients (pts) – are activating, sensitive to MET inhibition and can be conveniently detected using liquid biopsy (LBx). We report data from an ongoing single-arm phase II study of tepotinib, a highly selective MET inhibitor, in NSCLC pts with METex14 mutations identified by LBx or tumor biopsy (TBx) (NCT02864992). Methods: Pts with advanced WT EGFR/ALK NSCLC, prospectively enrolled via either LBx (?60 pts) or TBx (?60 pts, overlap anticipated) central RNA-based METex14 mutation testing, receive…
Dr. Sanjay Popat discusses the quality of life for patients using Brigatinib. Background: Results from ALTA-1L (NCT02737501), an international, multicenter trial, showed that brigatinib vs crizotinib as 1L ALK therapy significantly prolongs progression-free survival (PFS; HR: 0.49, 95% CI, 0.33, 0.74) in advanced ALK+ NSCLC. HRQoL was evaluated as a secondary objective. Methods: ALK+ NSCLC patients were randomized 1:1 to brigatinib 90 mg daily for 7 days, then 180 mg daily or crizotinib 250 mg twice daily as 1L ALK therapy; treatment cycles were 28 days. HRQoL was assessed with the EORTC QLQ-C30 and LC13. Change from baseline, duration of…
Dr. Michael Atkins MD Of Georgetown University Discusses Who Should Get Ipi:Nivo VS NIVO Monotherapy: Patients With Elevated LDH, BRAF Mutant Tumors, & Brain Metastases Benefit From Combination Therapy. BACKROUND: We previously reported a 3-year overall survival (OS) rate of 63% with NIVO+IPI concurrent therapy in the initial phase I dose-escalation study for the combination, conducted in patients (pts) with advanced melanoma. Here, we report OS after 5 years of overall study follow-up and assess survival rates after stopping treatment. METHODS: Adults with previously treated or untreated unresectable stage III or IV melanoma, and ECOG performance status of 0 or…
Dr. Michael Atkins MD Of Georgetown University Discusses CHECKMATE-004 Trial Results: 57% Of Patients Were Alive At 4 Years, Treatment Plan Was 2 Years, 23 Patients Completed Full Course. BACKROUND: We previously reported a 3-year overall survival (OS) rate of 63% with NIVO+IPI concurrent therapy in the initial phase I dose-escalation study for the combination, conducted in patients (pts) with advanced melanoma. Here, we report OS after 5 years of overall study follow-up and assess survival rates after stopping treatment. METHODS: Adults with previously treated or untreated unresectable stage III or IV melanoma, and ECOG performance status of 0 or…
Dr. Sanjay Popat discusses if East Asian patients tolerate Brigatinib any differently than Crizotinb. Background: We report an analysis of BRG vs CRZ in Asian vs non-Asian pts with ALK inhibitornaive, ALK+ NSCLC from ALTA-1L (NCT02737501). Methods: Pts were randomized 1:1 to BRG 180 mg QD (7-day lead-in at 90 mg) or CRZ 250 mg BID. Primary endpoint: blinded independent review committee (BIRC)-assessed PFS (RECIST v1.1). Secondary efficacy endpoints: BIRC-assessed ORR, intracranial (i) ORR, and iPFS. Results: 275 pts were randomized; 108 Asian (BRG/CRZ, n = 59/49), 167 non-Asian (n = 78/89); median age: Asian, 55/56 y; non-Asian, 60/60 y.…
Elad Sharon MD @EladSharonMD Of The National Cancer Institute Discusses Pembrolizumab Trial & Broadening Eligibility For HIV Patients: Patients With HIV Did Very Well With Pembrolizumab, The NCI Has Been Pushing To Broaden Eligibility. BACKROUND: People with HIV have been excluded from immuno-oncology (IO) studies. Anti- PD-1/PD-L1 therapies are approved for a growing number of cancers. We evaluated pembrolizumab (pembro) in people with HIV and cancer. METHODS: CITN-12 is a multicenter phase 1 trial. Key eligibility: advanced cancer; ECOG ?1; CD4 ?100 cells/?L; ?4 weeks antiretroviral therapy (ART), HIV viral load (VL) < 200 copies/mL. Exclusion: uncontrolled HBV/HCV, autoimmune disease.…
Nicholas Rohs MD @NickRohsMD Of Mount Sinai Discusses Combining Chemo & Immunotherapy Did Not Help Patients: Hope To See Survival Level Off As Data Matures.
Elizabeth R. Plimack MD MS @ERPlimackMD Of The Fox Chase Cancer Center Discusses Metastatic RCC Metastasectomy Study: Procedure Does Not Prolong Survival, Trend Towards Worse OS, No Benefit To Relapse Free Survival At 3 Years.
Dr. Sanjay Popat, PhD, disucsses the Phase 3 ALTA-1L sub-analyses. Background: We report an analysis of BRG vs CRZ in Asian vs non-Asian pts with ALK inhibitornaive, ALK+ NSCLC from ALTA-1L (NCT02737501). Methods: Pts were randomized 1:1 to BRG 180 mg QD (7-day lead-in at 90 mg) or CRZ 250 mg BID. Primary endpoint: blinded independent review committee (BIRC)-assessed PFS (RECIST v1.1). Secondary efficacy endpoints: BIRC-assessed ORR, intracranial (i) ORR, and iPFS. Results: 275 pts were randomized; 108 Asian (BRG/CRZ, n = 59/49), 167 non-Asian (n = 78/89); median age: Asian, 55/56 y; non-Asian, 60/60 y. 32/24% of Asians vs…
Katja Weisel from University Medical Center Hamburg-Eppendorf discusses the role of daratumumab in first line treatment. Background: MM patients (pts) with high cytogenetic risk have poor outcomes. In CASTOR, D-Vd prolonged progression-free survival (PFS) vs bortezomib and dexamethasone (Vd) alone, and exhibited tolerability in RRMM pts. We conducted a subgroup analysis of D-Vd vs Vd in CASTOR, based on cytogenetic risk. Methods: Pts received ?1 prior line of therapy. Cytogenetic risk was based on a combined analysis of next-generation sequencing (NGS) and fluorescence in situ hybridization/karyotype testing. High-risk pts had t(4;14), t(14;16), or del17p abnormalities. Standard (std)-risk pts were confirmed…
Katja Weisel from the University Medical Center Hamburg-Eppendorf discusses the efficacy and safety of daratumumab, bortezomib, and dexamethasone. Background: MM patients (pts) with high cytogenetic risk have poor outcomes. In CASTOR, D-Vd prolonged progression-free survival (PFS) vs bortezomib and dexamethasone (Vd) alone, and exhibited tolerability in RRMM pts. We conducted a subgroup analysis of D-Vd vs Vd in CASTOR, based on cytogenetic risk. Methods: Pts received ?1 prior line of therapy. Cytogenetic risk was based on a combined analysis of next-generation sequencing (NGS) and fluorescence in situ hybridization/karyotype testing. High-risk pts had t(4;14), t(14;16), or del17p abnormalities. Standard (std)-risk pts…
Armon Sharei PhD Of SQZ Biotech Discusses Trial Addressing HPV Positive Tumors: Enrolling Patients In Trial This Year, Looking At SQZ APC Technology To See If A Strong Immune Response Can Be Induced.
Background: MM patients (pts) with high cytogenetic risk have poor outcomes. In CASTOR, D-Vd prolonged progression-free survival (PFS) vs bortezomib and dexamethasone (Vd) alone, and exhibited tolerability in RRMM pts. We conducted a subgroup analysis of D-Vd vs Vd in CASTOR, based on cytogenetic risk. Methods: Pts received ?1 prior line of therapy. Cytogenetic risk was based on a combined analysis of next-generation sequencing (NGS) and fluorescence in situ hybridization/karyotype testing. High-risk pts had t(4;14), t(14;16), or del17p abnormalities. Standard (std)-risk pts were confirmed negative for all 3 abnormalities. Minimal residual disease (MRD; 105) was assessed via NGS using clonoSEQ…
Armon Sharei PhD Of SQZ Biotech Discusses SQZ Biotech: Engineer Multiple Facets Of Cell Function In A Very Practical Way, Addressing Accessibility & Cost Effectiveness Issues.
Armon Sharei PhD Of SQZ Biotech Discusses Questions About SQZ Biotech Technology: Use SQZ Platform To Deliver Antigens Directly Into The Cyto Cell Of APCs.
Lee Schwartzberg MD @oncstatdoc Of West Cancer Center Discusses Prophylaxis For CINV: Patients Should Be Treated With A Triple Combination To Get The Best Prophylaxis Against CINV. BACKROUND: NEPA, a combination antiemetic agent [NK1 receptor antagonist (RA) netupitant (oral) or fosnetupitant (IV) + 5-HT3RA palonosetron] offers 5-day CINV prevention with a single-dose. Unlike other IV NK1RAs, the fosnetupitant solution does not require a surfactant, emulsifier, or solubility enhancer and contains no allergenic excipients. In a Phase 3 study in pts receiving cisplatin-based CT, there were no infusion site or anaphylactic reactions related to IV NEPA. In contrast, hypersensitivity reactions and…
Lee Schwartzberg MD @oncstatdoc Of West Cancer Center Discusses Managing CINV: Developed New NK1 Receptor Antagonist, Clear Evidence Based Guidelines That Tell When To Use Triplet Or Double Combination. BACKROUND: NEPA, a combination antiemetic agent [NK1 receptor antagonist (RA) netupitant (oral) or fosnetupitant (IV) + 5-HT3RA palonosetron] offers 5-day CINV prevention with a single-dose. Unlike other IV NK1RAs, the fosnetupitant solution does not require a surfactant, emulsifier, or solubility enhancer and contains no allergenic excipients. In a Phase 3 study in pts receiving cisplatin-based CT, there were no infusion site or anaphylactic reactions related to IV NEPA. In contrast, hypersensitivity…
Lee Schwartzberg MD @oncstatdoc Of West Cancer Center Discusses Issues With CINV Remaining: If Guidelines Are Used Effectively A Large Majority Of Patients Will Not Have A Severe CINV Reaction. BACKROUND: NEPA, a combination antiemetic agent [NK1 receptor antagonist (RA) netupitant (oral) or fosnetupitant (IV) + 5-HT3RA palonosetron] offers 5-day CINV prevention with a single-dose. Unlike other IV NK1RAs, the fosnetupitant solution does not require a surfactant, emulsifier, or solubility enhancer and contains no allergenic excipients. In a Phase 3 study in pts receiving cisplatin-based CT, there were no infusion site or anaphylactic reactions related to IV NEPA. In contrast,…
Lee Schwartzberg MD @oncstatdoc Of West Cancer Center Discusses Intravenous NEPA Study: Combination Therapy To Prevent CINV In Patients Receiving Anthracycline/Cyclophosphamide (AC). BACKROUND: NEPA, a combination antiemetic agent [NK1 receptor antagonist (RA) netupitant (oral) or fosnetupitant (IV) + 5-HT3RA palonosetron] offers 5-day CINV prevention with a single-dose. Unlike other IV NK1RAs, the fosnetupitant solution does not require a surfactant, emulsifier, or solubility enhancer and contains no allergenic excipients. In a Phase 3 study in pts receiving cisplatin-based CT, there were no infusion site or anaphylactic reactions related to IV NEPA. In contrast, hypersensitivity reactions and anaphylaxis have been reported with…
Lee Schwartzberg MD @oncstatdoc Of West Cancer Center Discusses Akynzeo: Convient & Flexible Dosing, Can Be Given Orally & Intravenously. BACKROUND: NEPA, a combination antiemetic agent [NK1 receptor antagonist (RA) netupitant (oral) or fosnetupitant (IV) + 5-HT3RA palonosetron] offers 5-day CINV prevention with a single-dose. Unlike other IV NK1RAs, the fosnetupitant solution does not require a surfactant, emulsifier, or solubility enhancer and contains no allergenic excipients. In a Phase 3 study in pts receiving cisplatin-based CT, there were no infusion site or anaphylactic reactions related to IV NEPA. In contrast, hypersensitivity reactions and anaphylaxis have been reported with IV aprepitant,…
Nicholas Rohs MD @NickRohsMD Of Mount Sinai Discusses Updates In Esophageal & Gastric Cancers: When Dose Of Xeloda & Oxaliplatin Is Reduced In Frail Patients They Did Very Well & Had Less Toxicity.
Nicholas Rohs MD @NickRohsMD Of Mount Sinai Discusses Lower Doses Of Xeloda & Oxaliplatin: Physicians Would Be Happy To Give A Lower Dose If Data Supports.